Pharmacological Potential of Endothelin Receptors Agonists and Antagonists

Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with va...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Jiří Patočka [verfasserIn] Vladimír Měrka [verfasserIn] Vratislav Hrdina [verfasserIn] Radomír Hrdina [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2005

Schlagwörter:	Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment

Übergeordnetes Werk:	In: Acta Medica - Karolinum Press, 2004, 48(2005), 2, Seite 67-73
Übergeordnetes Werk:	volume:48 ; year:2005 ; number:2 ; pages:67-73

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.14712/18059694.2018.34

Katalog-ID:	DOAJ039212548

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ039212548
003	DE-627
005	20230308030026.0
007	cr uuu---uuuuu
008	230227s2005 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.14712/18059694.2018.34 \|2 doi
035			\|a (DE-627)DOAJ039212548
035			\|a (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Jiří Patočka \|e verfasserin \|4 aut
245	1	0	\|a Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
264		1	\|c 2005
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.
650		4	\|a Endothelin
650		4	\|a Endothelin receptor
650		4	\|a Endothelin receptor agonist
650		4	\|a Endothelin receptor antagonist
650		4	\|a Bosentan
650		4	\|a Pulmonary hypertension treatment
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Vladimír Měrka \|e verfasserin \|4 aut
700	0		\|a Vratislav Hrdina \|e verfasserin \|4 aut
700	0		\|a Radomír Hrdina \|e verfasserin \|4 aut
773	0	8	\|i In \|t Acta Medica \|d Karolinum Press, 2004 \|g 48(2005), 2, Seite 67-73 \|w (DE-627)320418170 \|w (DE-600)2002210-4 \|x 18059694 \|7 nnns
773	1	8	\|g volume:48 \|g year:2005 \|g number:2 \|g pages:67-73
856	4	0	\|u https://doi.org/10.14712/18059694.2018.34 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 \|z kostenfrei
856	4	0	\|u https://actamedica.lfhk.cuni.cz/48/2/0067/ \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1211-4286 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1805-9694 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 48 \|j 2005 \|e 2 \|h 67-73

Indexfelder

author_variant	j p jp v m vm v h vh r h rh
matchkey_str	article:18059694:2005----::hraooiaptnilfnohlneetrao
hierarchy_sort_str	2005
publishDate	2005
allfields	10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73
spelling	10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73
allfields_unstemmed	10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73
allfieldsGer	10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73
allfieldsSound	10.14712/18059694.2018.34 doi (DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7 DE-627 ger DE-627 rakwb eng Jiří Patočka verfasserin aut Pharmacological Potential of Endothelin Receptors Agonists and Antagonists 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents. Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R Vladimír Měrka verfasserin aut Vratislav Hrdina verfasserin aut Radomír Hrdina verfasserin aut In Acta Medica Karolinum Press, 2004 48(2005), 2, Seite 67-73 (DE-627)320418170 (DE-600)2002210-4 18059694 nnns volume:48 year:2005 number:2 pages:67-73 https://doi.org/10.14712/18059694.2018.34 kostenfrei https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 kostenfrei https://actamedica.lfhk.cuni.cz/48/2/0067/ kostenfrei https://doaj.org/toc/1211-4286 Journal toc kostenfrei https://doaj.org/toc/1805-9694 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 48 2005 2 67-73
language	English
source	In Acta Medica 48(2005), 2, Seite 67-73 volume:48 year:2005 number:2 pages:67-73
sourceStr	In Acta Medica 48(2005), 2, Seite 67-73 volume:48 year:2005 number:2 pages:67-73
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment Medicine R
isfreeaccess_bool	true
container_title	Acta Medica
authorswithroles_txt_mv	Jiří Patočka @@aut@@ Vladimír Měrka @@aut@@ Vratislav Hrdina @@aut@@ Radomír Hrdina @@aut@@
publishDateDaySort_date	2005-01-01T00:00:00Z
hierarchy_top_id	320418170
id	DOAJ039212548
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039212548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308030026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14712/18059694.2018.34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039212548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jiří Patočka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Potential of Endothelin Receptors Agonists and Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bosentan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pulmonary hypertension treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vladimír Měrka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vratislav Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radomír Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Medica</subfield><subfield code="d">Karolinum Press, 2004</subfield><subfield code="g">48(2005), 2, Seite 67-73</subfield><subfield code="w">(DE-627)320418170</subfield><subfield code="w">(DE-600)2002210-4</subfield><subfield code="x">18059694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:67-73</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14712/18059694.2018.34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://actamedica.lfhk.cuni.cz/48/2/0067/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1211-4286</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1805-9694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">67-73</subfield></datafield></record></collection>
author	Jiří Patočka
spellingShingle	Jiří Patočka misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
authorStr	Jiří Patočka
ppnlink_with_tag_str_mv	@@773@@(DE-627)320418170
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	18059694
topic_title	Pharmacological Potential of Endothelin Receptors Agonists and Antagonists Endothelin Endothelin receptor Endothelin receptor agonist Endothelin receptor antagonist Bosentan Pulmonary hypertension treatment
topic	misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R
topic_unstemmed	misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R
topic_browse	misc Endothelin misc Endothelin receptor misc Endothelin receptor agonist misc Endothelin receptor antagonist misc Bosentan misc Pulmonary hypertension treatment misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Acta Medica
hierarchy_parent_id	320418170
hierarchy_top_title	Acta Medica
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)320418170 (DE-600)2002210-4
title	Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
ctrlnum	(DE-627)DOAJ039212548 (DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7
title_full	Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
author_sort	Jiří Patočka
journal	Acta Medica
journalStr	Acta Medica
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2005
contenttype_str_mv	txt
container_start_page	67
author_browse	Jiří Patočka Vladimír Měrka Vratislav Hrdina Radomír Hrdina
container_volume	48
format_se	Elektronische Aufsätze
author-letter	Jiří Patočka
doi_str_mv	10.14712/18059694.2018.34
author2-role	verfasserin
title_sort	pharmacological potential of endothelin receptors agonists and antagonists
title_auth	Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
abstract	Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.
abstractGer	Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.
abstract_unstemmed	Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
url	https://doi.org/10.14712/18059694.2018.34 https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7 https://actamedica.lfhk.cuni.cz/48/2/0067/ https://doaj.org/toc/1211-4286 https://doaj.org/toc/1805-9694
remote_bool	true
author2	Vladimír Měrka Vratislav Hrdina Radomír Hrdina
author2Str	Vladimír Měrka Vratislav Hrdina Radomír Hrdina
ppnlink	320418170
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.14712/18059694.2018.34
up_date	2024-07-03T22:13:27.667Z
_version_	1803597704246329344
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ039212548</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308030026.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.14712/18059694.2018.34</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ039212548</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe6114750a1dc45e2b0ef522e39c826f7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jiří Patočka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacological Potential of Endothelin Receptors Agonists and Antagonists</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endothelins are potent predominantly vasoconstricting agents that act as local autocrine and paracrine mediators. Endothelin-1 is the most potent and sustained vasoconstrictor and pressor substance yet identified. Abnormalities of the endothelin system occur in a range of diseases associated with vasoconstriction, vasospasm, and vascular hypertrophy. ET receptor antagonists were until recently regarded as drugs of great promise in patients with congestive heart failure, pulmonary hypertension and others. The aim of this article is a survey of compounds that affect the endothelin receptors and clinical trials with these agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor agonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Endothelin receptor antagonist</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bosentan</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pulmonary hypertension treatment</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vladimír Měrka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vratislav Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radomír Hrdina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Medica</subfield><subfield code="d">Karolinum Press, 2004</subfield><subfield code="g">48(2005), 2, Seite 67-73</subfield><subfield code="w">(DE-627)320418170</subfield><subfield code="w">(DE-600)2002210-4</subfield><subfield code="x">18059694</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:48</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:67-73</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.14712/18059694.2018.34</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e6114750a1dc45e2b0ef522e39c826f7</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://actamedica.lfhk.cuni.cz/48/2/0067/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1211-4286</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1805-9694</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">48</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">67-73</subfield></datafield></record></collection>
score	7.3999805

Nicht das Richtige dabei?

Schreiben Sie uns!

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?